2021年(nian)12月18日，中(zhong)國中(zhong)藥(yao)(yao)協會(hui)(hui)四屆五次(ci)理(li)事(shi)會(hui)(hui)在京召(zhao)開。會(hui)(hui)議(yi)期(qi)間，以(yi)網(wang)絡直播方式隆重發布2021年(nian)度中(zhong)藥(yao)(yao)產(chan)業信息，九(jiu)芝堂疏血(xue)通注射液、六(liu)味地黃(huang)丸、天(tian)麻鉤藤顆粒榮(rong)登臨(lin)床價值(zhi)中(zhong)成藥(yao)(yao)品(pin)牌(pai)榜(bang)，九(jiu)芝堂股份有限公司榮(rong)登中(zhong)成藥(yao)(yao)企業TOP100榜(bang)單，位列第26位！

本次臨床價(jia)(jia)值(zhi)(zhi)中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)藥(yao)品牌榜評選以臨床價(jia)(jia)值(zhi)(zhi)為導向，依據(ju)協(xie)會發(fa)布的(de)《中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)品牌評價(jia)(jia) 通則》、《中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)品牌評價(jia)(jia) 中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)藥(yao)》、《中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)品牌評價(jia)(jia) 中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)飲(yin)片》團體(ti)標準共識中(zhong)(zhong)(zhong)(zhong)(zhong)推(tui)薦(jian)治療中(zhong)(zhong)(zhong)(zhong)(zhong)醫優勢病(bing)種的(de)中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)藥(yao)，結合(he)各省行業協(xie)會推(tui)薦(jian)和品牌專家組(zu)主(zhu)動研究，確(que)定(ding)臨床價(jia)(jia)值(zhi)(zhi)高、循(xun)證證據(ju)充分、臨床主(zhu)動功(gong)能(neng)獨特、品牌影響力(li)強(qiang)的(de)中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)藥(yao)及經(jing)典名(ming)方進入遴選范(fan)圍，并堅持負(fu)面清單一票否決原則。

天麻鉤藤顆粒(li)、疏(shu)血(xue)通注(zhu)射液(ye)、六(liu)味地黃丸位列榜(bang)單，既充分彰顯了九芝堂中成(cheng)藥產品臨床(chuang)價值，又有(you)助于九芝堂品牌影響力提升(sheng)！

中成藥(yao)企(qi)業(ye)(ye)TOP100榜(bang)(bang)單是通過企(qi)業(ye)(ye)產品信(xin)(xin)息(xi)征集(ji)、信(xin)(xin)息(xi)檢索(suo)和品牌專家組主動研(yan)究，參考(kao)工(gong)信(xin)(xin)部發(fa)布的(de)(de)醫藥(yao)統計(ji)年(nian)報百強企(qi)業(ye)(ye)，醫藥(yao)上(shang)市(shi)公司(si)統計(ji)年(nian)報數據，各(ge)新聞媒(mei)體(ti)和咨詢公司(si)發(fa)布的(de)(de)行業(ye)(ye)排行榜(bang)(bang)，中成藥(yao)企(qi)業(ye)(ye)上(shang)報信(xin)(xin)息(xi)，中藥(yao)行業(ye)(ye)大型分(fen)析報告中的(de)(de)相關信(xin)(xin)息(xi)，協會(hui)會(hui)員(yuan)單位基礎(chu)信(xin)(xin)息(xi)，協會(hui)承(cheng)擔課題中的(de)(de)相關信(xin)(xin)息(xi)，并依據企(qi)業(ye)(ye)主營業(ye)(ye)務收入、企(qi)業(ye)(ye)研(yan)發(fa)創新情況，堅持(chi)負面清單一票否決原則(ze)而產生。九芝堂(tang)榮耀上(shang)榜(bang)(bang)，是對(dui)九芝堂(tang)綜合實力、社(she)會(hui)影(ying)響力的(de)(de)充分(fen)肯定！

值得(de)一提的(de)是，會(hui)上，中(zhong)(zhong)國(guo)醫學院科學植物藥用(yong)研(yan)究(jiu)(jiu)所孫曉波(bo)所長作《2021年度臨床(chuang)價值中(zhong)(zhong)成藥品(pin)牌榜(bang)樣遴選基(ji)本情況匯報(bao)》，以九(jiu)芝堂“疏血(xue)通(tong)(tong)注(zhu)(zhu)射(she)液”為(wei)例(li)，向參會(hui)人員介紹了中(zhong)(zhong)藥注(zhu)(zhu)射(she)劑可(ke)評(ping)價，能(neng)(neng)夠得(de)到(dao)同行、尤其西醫的(de)認(ren)可(ke)。孫教授提到(dao)，疏血(xue)通(tong)(tong)注(zhu)(zhu)射(she)液SPACE研(yan)究(jiu)(jiu)完全以西醫單位為(wei)主(zhu)認(ren)定(ding)，充(chong)分(fen)肯定(ding)了產品(pin)療效(xiao)，急性(xing)(xing)期給與(yu)疏血(xue)通(tong)(tong)注(zhu)(zhu)射(she)液可(ke)以顯著降低患者15%的(de)復發風險(xian)，且不增(zeng)加出(chu)血(xue)等安(an)全性(xing)(xing)風險(xian)。同時疏血(xue)通(tong)(tong)注(zhu)(zhu)射(she)液能(neng)(neng)量(liang)代謝、新增(zeng)血(xue)管、改善循環作用(yong)機理基(ji)礎(chu)性(xing)(xing)研(yan)究(jiu)(jiu)扎實；進一步研(yan)究(jiu)(jiu)通(tong)(tong)過Meta分(fen)析，以大(da)量(liang)文獻證明(ming)了產品(pin)療效(xiao)；在(zai)安(an)全性(xing)(xing)、有(you)效(xiao)性(xing)(xing)、經(jing)濟性(xing)(xing)方面也得(de)到(dao)了充(chong)分(fen)的(de)肯定(ding)。孫教授指出(chu)，這項(xiang)研(yan)究(jiu)(jiu)未來會(hui)推(tui)動中(zhong)(zhong)成藥臨床(chuang)品(pin)牌價值設立。

進入新發(fa)展階段，尤其疫情以來，中(zhong)(zhong)(zhong)醫藥迎來了前所未有的(de)戰略(lve)機(ji)遇期。九芝堂(tang)作(zuo)為(wei)中(zhong)(zhong)(zhong)華老字號(hao)企(qi)業(ye)、中(zhong)(zhong)(zhong)醫藥文化典(dian)型代表，以“在傳承中(zhong)(zhong)(zhong)創(chuang)新，在創(chuang)新中(zhong)(zhong)(zhong)發(fa)展”為(wei)發(fa)展理念(nian)，一直(zhi)致(zhi)力于傳承好、發(fa)展好中(zhong)(zhong)(zhong)醫藥事(shi)業(ye)，為(wei)建(jian)設健康中(zhong)(zhong)(zhong)國貢獻力量！